Rachael L. Morton

Rachael L. Morton is an Australian academic, Professor and Principal Research Fellow of Health Economics in the Faculty of Medicine and Health at the University of Sydney.[1] Morton is an international leader in the economic evaluation of chronic kidney disease and melanoma.[2]

Education and Career

Morton graduated with a PhD from the University of Sydney in 2011.[3]

Morton is currently Director of Health Economics & Health Technology Assessment and deputy director of the NHMRC Clinical Trials Centre.[1]

Board Director, Australian Clinical Trials Alliance[4] (ACTA) 2018–2024; Past President, Heath Services Research Association Australia and New Zealand[5] (HSRAANZ); Program Chair - International Health Economics Association[6] (IHEA); Health Economists Study Group UK[7] (HESG).[1]

Health Economics Research

Morton is an international leader in the economic evaluation of chronic kidney disease and melanoma prevention, diagnosis, and treatment.[8]

Morton's research has had a major influence on funding policy (US Medicare & Medicaid) for dialysis payments and chronic kidney disease;[9] Australian Medicare providing economic evidence for new MBS items.[10] Her research has changed international clinical practice guidelines in melanoma (UK, US, Germany, Brazil, Australia[11]) kidney disease (Kidney Disease Improving Global Outcomes [KDIGO] guidelines,[12] CARI [Australia]), for transplantation and end-of-life care; and infectious diseases through the European Centre for Disease Control [EU].

Awards and recognition

In 2013 Morton won an NHMRC Sidney Sax Fellowship to Oxford University.[13]

In 2019 CI Morton won the Distinguished Investigator award for Health Services Research.[14]

In 2024, Morton won the ACTA Trial of the Year, Health Economics Alongside Trials (HEAT) Excellence award for her high impact cost-effectiveness analysis of a melanoma prevention strategy using personalised genomics.[15][16]

Additionally in 2024, Morton was a winner in the Eureka Science Prize – Aspire Scholarship Excellence in Interdisciplinary Scientific Research, for the ACRF Australian Centre for Excellence in Melanoma Imaging and Diagnosis.[17]

Top Publications

Source:[18]

  • The views of patients and carers in treatment decision making for chronic kidney disease: a systematic review and thematic synthesis of qualitative studies. BMJ.[19]
  • Chronic Kidney Disease. The Lancet.[20]
  • Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma. Journal of Clinical Oncology.[21]
  • The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review. Euro Surveillance.[22]
  • Impact of CKD on Household Income. Kidney International Reports.[23]
  • Incorporating carbon into health care: adding carbon emissions to health technology assessments. The Lancet Planetary Health.[24]
  • The Symptom Monitoring with Feedback Trial (SWIFT): Protocol for a registry-based cluster randomised controlled trial in haemodialysis. Trials.[25]
  • Patient- reported outcome measures (PROMs) to guide clinical care: recommendations and challenges. MJA.[26]
  • Kidney health in the context of economic development. Nature Reviews, Nephrology.[27]
  • Expedited transfer from scene for refractory out-of-hospital cardiac arrest: an Australian prospective, multicentre, parallel, open-label randomised clinical trial. Accepted The Lancet Respiratory Medicine. (May, 2025)

References

  1. 1 2 3 Morton, Rachael (2025-07-21). "People". The University of Sydney.
  2. ↑ "Professor Rachael Morton". Melanoma Institute Australia.
  3. ↑ Morton, Rachael (2025-07-21). "Profile/rachaelmorton". Linked In.
  4. ↑ "ACTA – Australian Clinical Trials Alliance – Better health through best evidence". clinicaltrialsalliance.org.au.
  5. ↑ "HSRAANZ - Using research to improve health services & systems". HSRAANZ.
  6. ↑ "Home". IHEA.
  7. ↑ "Health Economists' Study Group – The UK Health Economics Association". March 1, 2019.
  8. ↑ Health Services Research Association of Australia and New Zealand. "Rachael Morton – Executive Member". HSRAANZ. Retrieved 2025-07-22.
  9. ↑ Walker, Rachael C.; Howard, Kirsten; Tong, Anthony; Palmer, Suetonia C.; Marshall, Mark R.; Morton, Rachael L. (2016). "The economic considerations of patients and caregivers in choice of dialysis modality". Hemodialysis International. 20 (4): 634–642. doi:10.1111/hdi.12424. PMC 5324572. Retrieved 2025-07-22.
  10. ↑ "Application No. 1485.1 – Sentinel Lymph Node Biopsy for intermediate thickness melanoma" (PDF). www.msac.gov.au.
  11. ↑ "Clinical practice guidelines for the diagnosis and management of melanoma". Cancer Council Australia. Archived from the original on 2023-11-13.
  12. ↑ Davison, Sara N.; Levin, Adeera; Moss, Alvin H.; Jha, Vivekanand; Brown, Edwina A.; Brennan, Frank; Murtagh, Fliss E. M.; Naicker, Saraladevi; Germain, Michael J.; O'Donoghue, Donal J.; Morton, Rachael L.; Obrador, Gregorio T. (2015-09-01). "Executive summary of the KDIGO Controversies Conference on Supportive Care in Chronic Kidney Disease: developing a roadmap to improving quality care". Kidney International. 88 (3): 447–459. doi:10.1038/ki.2015.110. ISSN 0085-2538. PMID 25923985.
  13. ↑ Green, Sarah (2019-12-12). "A/Professor Rachael Morton – Distinguished Investigator (Mid-Career)". Health Services Research Association of Australia and New Zealand. Retrieved 2025-07-22.
  14. ↑ Green, Sarah (2019-12-12). "A/Professor Rachael Morton - Distinguished Investigator (Mid-Career)". HSRAANZ. Retrieved 2025-07-22.
  15. ↑ "NHMRC Clinical Trial Centre | Improving Health Outcomes". ctc.usyd.edu.au. Retrieved 2025-07-21.
  16. ↑ "Australian Clinical Trials shine at annual ACTA Awards – ACTA – Australian Clinical Trials Alliance". clinicaltrialsalliance.org.au. 2024-05-20. Retrieved 2025-07-21.
  17. ↑ "2024 Australian Museum Eureka Prizes finalists". The Australian Museum. Retrieved 2025-07-21.
  18. ↑ "Rachael Morton". scholar.google.com.au. Retrieved 2025-07-21.
  19. ↑ Morton, R. L.; Tong, A.; Howard, K.; Snelling, P.; Webster, A. C. (2010-01-19). "The views of patients and carers in treatment decision making for chronic kidney disease: systematic review and thematic synthesis of qualitative studies". BMJ. 340: c112. doi:10.1136/bmj.c112. ISSN 0959-8138. PMC 2808468. PMID 20085970.
  20. ↑ Webster, Angela C.; Nagler, Evi V.; Morton, Rachael L.; Masson, Philip (2017-03-25). "Chronic Kidney Disease". The Lancet. 389 (10075): 1238–1252. doi:10.1016/S0140-6736(16)32064-5. ISSN 0140-6736. PMID 27887750.
  21. ↑ Watts, Caroline G.; Cust, Anne E.; Menzies, Scott W.; Mann, Graham J.; Morton, Rachael L. (January 2017). "Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma". Journal of Clinical Oncology. 35 (1): 63–71. doi:10.1200/JCO.2016.68.4308. hdl:2123/30021. ISSN 0732-183X. PMID 28034073.
  22. ↑ Greenaway, Christina; Pareek, Manish; Abou Chakra, Claire-Nour; Walji, Moneeza; Makarenko, Iuliia; Alabdulkarim, Balqis; Hogan, Catherine; McConnell, Ted; Scarfo, Brittany; Christensen, Robin; Tran, Anh; Rowbotham, Nick; van der Werf, Marieke J.; Noori, Teymur; Pottie, Kevin (April 2018). "The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review". Euro Surveillance. 23 (14): 17–00543. doi:10.2807/1560-7917.ES.2018.23.14.17-00543. ISSN 1560-7917. PMC 5894253. PMID 29637889.
  23. ↑ Morton, Rachael L.; Schlackow, Iryna; Gray, Alastair; Emberson, Jonathan; Herrington, William; Staplin, Natalie; Reith, Christina; Howard, Kirsten; Landray, Martin J.; Cass, Alan; Baigent, Colin; Mihaylova, Borislava; Collins, R.; Baigent, C.; Landray, M. J. (2018-05-01). "Impact of CKD on Household Income". Kidney International Reports. 3 (3): 610–618. doi:10.1016/j.ekir.2017.12.008. ISSN 2468-0249. PMC 5976816. PMID 29854968.
  24. ↑ McAlister, Scott; Morton, Rachael L.; Barratt, Alexandra (2022-12-01). "Incorporating carbon into health care: adding carbon emissions to health technology assessments". The Lancet Planetary Health. 6 (12): e993–e999. doi:10.1016/S2542-5196(22)00258-3. hdl:2123/30261. ISSN 2542-5196. PMID 36495894.
  25. ↑ Greenham, Lavern; Bennett, Paul N.; Dansie, Kathryn; Viecelli, Andrea K.; Jesudason, Shilpanjali; Mister, Rebecca; Smyth, Brendan; Westall, Portia; Herzog, Samuel; Brown, Chris; Handke, William; Palmer, Suetonia C.; Caskey, Fergus J.; Couchoud, Cecile; Simes, John (2022-05-19). "The Symptom Monitoring with Feedback Trial (SWIFT): protocol for a registry-based cluster randomised controlled trial in haemodialysis". Trials. 23 (1): 419. doi:10.1186/s13063-022-06355-0. ISSN 1745-6215. PMC 9118566. PMID 35590395.
  26. ↑ "Patient-reported outcome measures (PROMs) to guide clinical care: recommendations and challenges" (PDF). www.mja.com.au.
  27. ↑ Morton, Rachael L.; Shah, Karan K. (January 2021). "Kidney health in the context of economic development". Nature Reviews Nephrology. 17 (1): 5–6. doi:10.1038/s41581-020-00376-1. ISSN 1759-507X. PMC 7684194. PMID 33235390.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.